PNC Financial Services Group Inc. Lowers Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

PNC Financial Services Group Inc. lessened its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 7.8% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 15,899 shares of the biotechnology company’s stock after selling 1,337 shares during the period. PNC Financial Services Group Inc.’s holdings in BioCryst Pharmaceuticals were worth $119,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $33,000. GAMMA Investing LLC increased its stake in shares of BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 5,449 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth $79,000. Raymond James Financial Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth $80,000. Finally, Syon Capital LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth $99,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director directly owned 65,352 shares of the company’s stock, valued at $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

BCRX has been the topic of a number of research reports. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Bank of America increased their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, July 1st. Barclays raised their price target on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 7th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.70.

BioCryst Pharmaceuticals Trading Down 1.2%

NASDAQ:BCRX opened at $8.28 on Wednesday. The company’s 50-day moving average price is $8.95 and its 200-day moving average price is $8.79. The company has a market cap of $1.74 billion, a P/E ratio of -46.00, a P/E/G ratio of 1.90 and a beta of 1.10. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analysts’ expectations of $149.59 million. During the same period last year, the firm earned ($0.06) earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 49.5% on a year-over-year basis. On average, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.